<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1728">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138666</url>
  </required_header>
  <id_info>
    <org_study_id>2021/656</org_study_id>
    <nct_id>NCT05138666</nct_id>
  </id_info>
  <brief_title>Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions.</brief_title>
  <acronym>BM-ASP-ICU</acronym>
  <official_title>Non-invasive Tools to Better Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Non-immunosuppressive Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive aspergillosis (IA) are difficult to diagnose in the ICU population, as the patients&#xD;
      often do not present the conventional risks factors of immunocompromised patients (EORTC/MSG&#xD;
      criteria). In the ICU population, patients often present other risk factors, such as&#xD;
      cirrhosis, COPD, influenza and currently SARS-Cov2. The clinicians are thus currently missing&#xD;
      precise criteria to distinguish colonization from IA in these patients, while they need to&#xD;
      decide if an antifungal treatment is necessary or not.&#xD;
&#xD;
      A new algorithm, entitled BM ASP ICU, based on investigators field experience and the&#xD;
      scientific literature, which takes into account both EORTC/MSG criteria and a combination of&#xD;
      fungal biomarkers, was proposed recently by Haman et al, Annals Intensive Care, 2021.&#xD;
      Additional serological assays (immunoprecipitation and ELISA) showed since their interest,&#xD;
      especially concerning SARS-Cov2 patients, a new population at risk of IA in the ICU, which&#xD;
      emerged in the past months.&#xD;
&#xD;
      The present study aims at prospectively implementing the BM ASP ICU algorithm during two&#xD;
      years in the routine practice of six ICU units distributed in general and teaching hospitals&#xD;
      situated northeast of France. The BM ASP ICU algorithm would be completed by serological&#xD;
      assays aiming at assessing a sensitization towards Aspergillus fumigatus.&#xD;
&#xD;
      The investigators plan to include 400 ICU patients at risk of IA; SARS-Cov2 patients will be&#xD;
      part of the cohort. A weekly screening including culture of respiratory samples,&#xD;
      galactomannan antigen, fungal qPCRS (targeting A. fumigatus), and A. fumigatus serology will&#xD;
      be applied for all included patients.&#xD;
&#xD;
      The performance (sensitivity and specificity, likelihood ratios) of each fungal biomarkers,&#xD;
      alone and in combination with others, will be assessed, for all patients, and also within&#xD;
      subgroups of patients with specific risk factors (such as SARS-Cov2 for example).&#xD;
&#xD;
      These results should lead to solid understanding of which combination of tests is optimal to&#xD;
      diagnose IA and thus to initiate appropriate antifungal treatment. the investigators hope&#xD;
      that this study will result in improved survival rate of ICU patients with IA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance indicators of the algorithm</measure>
    <time_frame>90 days</time_frame>
    <description>sensitivity, specificity, positive and negative predictive values, and likelihood ratios.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">363</enrollment>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>biological sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>respiratory and blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>respiratory sample</intervention_name>
    <description>tracheal aspirate or sputum if the patient is not intubated</description>
    <arm_group_label>biological sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood sampling drawn from an existing arterial line twice a week</description>
    <arm_group_label>biological sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ICU adult patient (age &gt; 18 years old at inclusion)&#xD;
&#xD;
          2. Patient with respiratory distress (fever refractory to &gt; 3 days of antibiotherapy,&#xD;
             pleuritic chest pain, hemoptysis) or Patient with sign of infection on thoracic scan&#xD;
             or Patient with positive culture for Aspergillus sp on any respiratory sample&#xD;
&#xD;
          3. Informed consent signed by the patient or proxy&#xD;
&#xD;
          4. Patient with health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Minor patient (age &lt; 18 years old at inclusion)&#xD;
&#xD;
          2. Known risk of immunodepression as defined by EORTC/MSG:&#xD;
&#xD;
               -  Recent history neutropenia (&lt; 500 neutrophils/mm3 for &gt; 10 days)&#xD;
&#xD;
               -  Haematological malignancy&#xD;
&#xD;
               -  Receipt of an allogenic stem cell transplant&#xD;
&#xD;
               -  Receipt of a solid organ transplant&#xD;
&#xD;
               -  Prolonged use of corticosteroids (excluding among patients with allergic&#xD;
                  bronchopulmonary aspergillosis) at a therapeutic dose of ≥0·3 mg/kg&#xD;
                  corticosteroids for ≥3 weeks in the past 60 days&#xD;
&#xD;
               -  Treatment with recognized T-cell immunosuppressant for more than 90 days (such as&#xD;
                  calcineurin inhibitors, TNF blockers, lymphocyte-specific monoclonal antibodies,&#xD;
                  and immunosuppressive nucleoside analogues)&#xD;
&#xD;
               -  Treatment with recognized inhibitors of B-cell receptor pathway (e. g,&#xD;
                  ibrutinib), possibly BCL2 inhibitors (e. g, venetoclax)&#xD;
&#xD;
               -  Inherited severe immunodeficiency (e. g, chronic granulomatous disease, STAT3&#xD;
                  deficiency, or severe combined immunodeficiency)&#xD;
&#xD;
               -  Acute graft-versus-host disease grade III or IV, involving the gut, lungs, or&#xD;
                  liver, that is refractory to first-line treatment with steroids&#xD;
&#xD;
          3. Patient under legal protection (e. g, tutorship)&#xD;
&#xD;
          4. Patients without health insurance&#xD;
&#xD;
          5. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Chrisptophe NAVELLOU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence MILLON, MD</last_name>
    <phone>0370632353</phone>
    <email>lmillon@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Chrisptophe NAVELLOU, MD</last_name>
    <phone>0381668212</phone>
    <email>jcnavellou@chu-besancon.fr</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICU patients</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

